Topic resource collection
Approved comparison material connected to this topic.
1378 resourcesRead both sides
CNS-Active Peptides Stanford, Johns Hopkins, UC San Diego Lipidated Dihexa analogues: 4.2× BBB penetration; cerebrolysin mechanism mapped; P21 cognitive improvement in MCI Phase 2 (P21 complete); Phase 1 (lipidated Dihexa analogu…
Before selecting a peptide for immune modulation, understanding the specific immune pathway each targets prevents mismatches between mechanism and goal. The table below compares the three highest-evidence peptides across immune f…
BPC-157 VEGF upregulation for mucosal repair, angiogenesis in damaged tissue 250–500 mcg SC daily or 1–2 mg oral daily 7–14 days for measurable barrier improvement Rodent colitis models show 40–60% lesion reduction in 14 days; hu…
DSIP Direct hypothalamic delta-wave modulation 12–18 minutes (animal models, limited human data) Increases slow-wave sleep (SWS) by 22–38% 30–60 minutes Moderate. Strong preclinical, sparse human RCTs Best direct sleep-onset agen…
GLP-1/GIP Receptor Agonists Survodutide, Mazdutide $195–$240 $145–$175 22–27% Highest synthesis complexity. October 2026 pricing represents rare opportunity on premium metabolic compounds that rarely see meaningful discounts Grow…
Short-acting GH secretagogues GHRP-2, Hexarelin 30–90 minutes 2–3× daily Renal filtration, enzymatic degradation Mimics pulsatile endogenous hormone release; requires strict timing but avoids receptor desensitization from constan…
Survodutide GLP-1/glucagon dual agonist 18.6% mean body weight reduction at 72 weeks; 12–14% RMR increase sustained without appetite escalation Adults with obesity (BMI ≥30) or overweight with comorbidity Phase 3 (SYNCHRONIZE tri…
Tirzepatide GIP/GLP-1 dual agonist 23.1% body weight reduction 104 weeks Exceeds single-pathway GLP-1 outcomes by 35–40%; rivals bariatric surgery without invasion Survodutide GLP-1/glucagon dual agonist 18.7% weight loss, 92% le…
Before selecting peptides for metabolic, cognitive, or immune research protocols, understanding mechanism-specific advantages across compound classes prevents mismatched applications and wasted resources. Survodutide Dual GLP-1/g…
Erectile Dysfunction VPAC2 receptor activation in corpus cavernosum smooth muscle → cAMP elevation → PKA-mediated vasodilation independent of NO pathway Phase 2 trials completed (1990s–2000s); intracavernosal injection formulatio…
Survodutide GLP-1/GIP/Glucagon triple agonist ~160 hours Metabolic syndrome, obesity models 2–8°C refrigerated Most comprehensive metabolic modulator. Addresses insulin resistance, appetite, and hepatic fat oxidation simultaneous…
Solid-Phase Synthesis (SPPS) 95–99.5% (verified by HPLC-MS) Exact amino acid sequencing with <0.1% error rate <2% variability between batches $50–$200/g for short peptides (5–20 AA); $500–$2,000/g for longer sequences (30–50 AA) …
| Peptide | Primary Mechanism | Recovery Target | Typical Research Dose | Time to Effect | Professional Assessment ||—|—|—|—|—|| Thymalin | Thymic epithelial cell stimulation, T-cell maturation | Immune suppression, illness frequ…
Growth Hormone Secretagogues (MK 677, GHRP-2) 18–25% Low–Medium (10–15 amino acids) −20°C lyophilized; 2–8°C reconstituted GH pathway studies, metabolic research, muscle tissue analysis Best value in July deals. High research dem…
| Peptide | Primary Mechanism | Injury Type Efficacy | Typical Dose Range | Administration Route | Evidence Grade (A–D) | Professional Assessment ||—|—|—|—|—|—|| BPC-157 | VEGF upregulation, angiogenesis | Tendon, ligament, muscl…
The following table compares the best peptides for chronic inflammation by mechanism, evidence base, and typical research dosing protocols used in published studies. BPC-157 VEGFR2 agonism, angiogenesis promotion, NF-κB modulatio…
The table below compares the most effective peptide protocols for body recomposition based on mechanism, dosing logistics, and expected outcomes over a 12-week cycle. CJC-1295/Ipamorelin GHRH/GHRP synergy. Pulsatile GH/IGF-1 elev…
Before selecting peptides for a cardiac research protocol, understanding mechanism class, primary target, and appropriate disease model prevents the common mistake of using ischemia-focused peptides in chronic failure studies or …
GnRH Analogs Hypothalamic-pituitary axis ART protocols, ovulation induction models, hypogonadism studies Receptor agonism (short-term stimulation) or desensitization (long-term suppression) Require precise sequencing at positions…
Understanding which peptide modulates which pathway is essential for experimental design. The table below compares four commonly researched peptides by their primary mechanism, receptor targets, evidence base, and typical researc…